Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05937841 · ClinicalTrials.gov registry record · Early Phase 1
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
A Early Phase 1 study of Preeclampsia Postpartum, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05937841 is a Early Phase 1 study of Preeclampsia Postpartum that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 30 participants, below the 70-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05937841, a Early Phase 1 study of Preeclampsia Postpartum, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
Conditions Studied
Interventions
- DRUG Compound 21
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2026-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05937841
The ClinicalTrials.gov registry entry for NCT05937841 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (57% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preeclampsia Postpartum appearing as the primary indexed condition, and to 1 intervention - of which Compound 21 is the first listed.
NCT05937841 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05937841 about?
NCT05937841 is a clinical study titled "Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia". Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that o...
What is the current status of trial NCT05937841?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-28. Estimated completion is 2026-06-01.
What conditions does trial NCT05937841 study?
This clinical trial studies the following conditions: Preeclampsia Postpartum.
What interventions are being tested in trial NCT05937841?
The interventions under investigation include: Compound 21 (DRUG).
Who is sponsoring clinical trial NCT05937841?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05937841 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia Postpartum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
-
Aspirin for Postpartum Patients With Preeclampsia
RECRUITING · Phase 2
-
Postpartum Low-Dose Aspirin and Preeclampsia
RECRUITING · Phase 2
-
Aspirin and Preeclampsia
RECRUITING · Phase 4
-
Preeclampsia Educational Program Study (PrEPS)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.